Human Papilloma Virus Clinical Trial
Official title:
Text Reminders to Immunize in a Managed Care Organization
The purpose of the study is to evaluate the effectiveness of a managed care-based HPV
vaccination reminder/recall system using a randomized controlled trial (RCT) across diverse
practices and patient populations. The trial will measure the effectiveness of text
messaging reminder/recall on (a) improving initiation and (b) completion rate of the HPV
vaccine series; (c) decreasing the time between vaccine doses; and (d) improving rates of
preventive visits for adolescents
The hypotheses are that text-messaged reminders to parents of adolescents will result in
improved rates of HPV vaccine series initiation, HPV vaccine series completion, will
decrease the intervals between vaccine doses and will improve rates of preventive care among
adolescents. Parents receiving specific text-messaged reminders about services (i.e. HPV
vaccination, well child care visits) for which their adolescent is due will be compared to a
control group of parents receiving general health tips through text messages.
The study setting is western New York State and the Southern Tier of New York State (15
counties total). Investigators will work with the Monroe Plan for Medical Care, an IPA-model
managed care organization (MCO) that serves Medicaid managed care and SCHIP enrollees. The
MCO will conduct regular reviews of insurance claims data and the New York State
Immunization Information System of adolescents ages 11-<18 years. Parents (all over 18 years
of age) of adolescents will receive the texted messages on their phones.
There are no enrollment restrictions based upon race or ethnic origin. The inclusion
criteria are that the adolescents are a) enrolled in Medicaid or SCHIP through the Monroe
Plan, b) have been enrolled greater than 6 months with the Monroe Plan (in order to have
sufficient claims data to determine whether they are due for a well child care visit or
recommended immunizations), c) the Monroe Plan has received their consent to send preventive
care text messages, d) their child attend a primary care practice that has agreed to
participate and d) they are between the ages of 11-<18 years at the start of the study.
The key independent measure is group allocation (intervention vs. control); an
intention-to-treat strategy will be used to assess the effectiveness of text messaging
reminders. Key outcome measures will be: 1) receipt of 0, 1, 2 or 3 doses of HPV vaccine 2)
interval (in days) between doses and 3) having a preventive visit in the 6 month period.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05329961 -
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
|
Early Phase 1 | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Active, not recruiting |
NCT04199078 -
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
|
N/A | |
Recruiting |
NCT05566106 -
Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
|
||
Not yet recruiting |
NCT06436274 -
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
|
Phase 4 | |
Not yet recruiting |
NCT06229353 -
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
|
||
Completed |
NCT01757392 -
Candin Safety & Efficacy Study for the Treatment of Warts
|
Phase 2 | |
Active, not recruiting |
NCT04716127 -
A Proximity-incentive Strategy for Cervical Cancer Screening
|
N/A | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Recruiting |
NCT05835947 -
Anal Cancer Risk In Women
|
||
Not yet recruiting |
NCT03947775 -
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
|
Phase 2 | |
Terminated |
NCT03404310 -
Zinc Sulfate for Human Papillomavirus (HPV)
|
N/A | |
Recruiting |
NCT03302858 -
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand
|
Phase 2 | |
Completed |
NCT03082950 -
HPV Infections, Cancer of the Vulva and Therapeutical Success
|
||
Active, not recruiting |
NCT04950101 -
Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis
|
N/A | |
Recruiting |
NCT05146895 -
A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts
|
N/A | |
Completed |
NCT04002154 -
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
|
N/A | |
Recruiting |
NCT04232917 -
Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.
|
Phase 4 | |
Active, not recruiting |
NCT03729518 -
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
|
N/A | |
Recruiting |
NCT05640700 -
Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
|